ERBB2 and breast cancer: As shown in Figure S1A,B, dose–response curves showed selective cell growth inhibition in HER2+ cell lines (AU565 and BT474) upon exposure to single-agent trastuzumab, as well as greater growth inhibition in response to single-agent docetaxel in HER2+, as compared to HER2-negative (MCF7 and ZR75-1), breast cancer cell lines (Table S2).